Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.

Hang QuachAjay NookaOlga SamoylovaChristopher P VennerKihyun KimThierry FaconAndrew SpencerSaad Z UsmaniSebastian GrosickiKenshi SuzukiSosana DelimpasiKatja WeiselMihaela ObrejaAnita Zahlten-KumeliMaria-Victoria Mateos-Manteca

Published in: British journal of haematology (2021)

Keyphrases

multiple myeloma
phase iii
open label
clinical trial
low dose
high dose
acute lymphoblastic leukemia
stem cells
placebo controlled
mesenchymal stem cells
smoking cessation
cell therapy
hodgkin lymphoma
replacement therapy